EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSMOCG00000005390
Gene Symbol: PSMD1
3 Cross references
210 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSMOCG00000020324
Gene Symbol: PSMD12
3 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSMOCG00000012233
Gene Symbol: PSMD13
3 Cross references
218 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSMOCG00000003211
Gene Symbol: PSMD14
3 Cross references
211 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 2

Ensembl ID : ENSMOCG00000016565
Gene Symbol: PSMD2
3 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 3

Ensembl ID : ENSMOCG00000019672
Gene Symbol: PSMD3
3 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 4

Ensembl ID : ENSMOCG00000022068
Gene Symbol: PSMD4
3 Cross references
289 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSMOCG00000000946
Gene Symbol: PSMD6
3 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSMOCG00000018363
Gene Symbol: PSMD7
3 Cross references
238 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSMOCG00000016263
Gene Symbol: PSMD8
3 Cross references
172 Possible Orthologues:

Proteasome Subunit Beta Type-3-Like

Ensembl ID : ENSMOCG00000017718
Gene Symbol: LOC101991843
2 Cross references
213 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSMOCG00000017320
Gene Symbol: PRMT5
3 Cross references
198 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).